Overview

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Status:
Completed

Trial end date:
2020-02-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL).

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin